转自：新华财经 据介绍，广药集团是全球首家以中医药为主业的世界500强企业，也是广东省、广州市生物医药产业"链 主"企业，拥有成员企业30多家，当前正以"现代化、科技化、数字化、国际化"四轮驱动，向世界一流 医药健康企业目标加速迈进。阿里健康近年来持续强化"新特药首发阵地"的定位，致力于为全球药企提 供从药品首发、渠道建设到患者服务的全链路支持，目前阿里健康已成为全球数千家医药企业的合作伙 伴。 编辑：胡晨曦 新华财经北京12月24日电（记者沈寅飞）记者从阿里健康获悉，近日，阿里健康与广药集团签署战略合 作协议。双方将聚焦深化平台与供应链合作、共建家庭过期药品回收体系、探索联合开发联名产品、推 进合规数据共享四大核心领域开展深度合作。 "我们将共享洞察、共创新产品，并打通线上线下一体化服务，让广药的优质产品能更高效、更精准地 触达全国亿万家庭。"阿里健康自营事业部总经理、药品平台业务部总经理章泽表示，此次合作标志着 双方从销售协同进入全域数字化运营与全链路服务共建的新阶段。 广药集团党委副书记、副董事长、总经理陈杰辉说，医药行业未来发展空间十分广阔，此次双方达成战 略合作，以"医药+互联网"融合创新打造健康新 ...

Core Viewpoint - The company Zhongyao Holdings (000950.SZ) has made significant progress in its share repurchase plan, indicating a commitment to enhancing shareholder value while facing challenges in profitability due to industry pressures [1][2]. Group 1: Share Repurchase Progress - As of August 31, Zhongyao Holdings has repurchased 9.313 million shares, accounting for approximately 0.54% of its total share capital, with a total expenditure of about 49.99 million yuan [1]. - The repurchase plan, initiated on July 11, aims to buy back shares worth between 80 million yuan and 100 million yuan, with a maximum price of 6.6 yuan per share [1]. Group 2: Financial Performance - Revenue has shown a steady increase over the past three years, with figures of 67.83 billion yuan in 2022, 78.4 billion yuan in 2023, and projected 80.56 billion yuan in 2024, reflecting successful business expansion [1]. - However, net profit has declined for three consecutive years, with figures of 0.952 billion yuan in 2022, 0.625 billion yuan in 2023, and 0.283 billion yuan in 2024, representing decreases of 5.29%, 34.41%, and 54.69% respectively [2]. Group 3: Recent Developments and Market Expansion - In the first half of 2025, the company achieved a revenue of 41.188 billion yuan, a year-on-year increase of 3.54%, and a net profit of 0.282 billion yuan, up 18.56% [2]. - The company has expanded its market presence, achieving coverage in all 31 provinces and 164 prefecture-level cities, with 65.85% of revenue coming from outside its home base in Chongqing [2]. - The pharmaceutical wholesale business generated over 95% of revenue, amounting to 39.052 billion yuan, while the e-commerce segment saw a transaction volume of approximately 1 billion yuan, growing by 72% [2][3]. Group 4: Retail and Asset Growth - The retail segment reported revenue of 1.947 billion yuan, with over 850 stores across 22 provinces, and has implemented services in 616 stores in response to national policies [3]. - As of mid-2025, total assets reached 67.95 billion yuan, a 2.57% increase year-on-year, while the debt-to-asset ratio improved to 75.61%, down by 0.67 percentage points [3].

Core Insights - The company reported a revenue of 41.188 billion yuan for the first half of 2025, representing a year-on-year growth of 3.54% [1] - The net profit attributable to shareholders was approximately 282 million yuan, with a year-on-year increase of 18.56% [1] - The basic earnings per share reached 0.16 yuan, reflecting a growth of 14.29% year-on-year [1] Business Overview - The company is a national wholesale enterprise for narcotic drugs and Class I psychotropic drugs, and it operates in the pharmaceutical and medical device sectors [1] - The main business segments include pharmaceutical commercial operations, covering drug sales, medical devices, traditional Chinese medicine, health products, and supply chain services [1] - The company has expanded its market presence, achieving coverage in all 31 provinces and 164 prefecture-level cities in China [1] Pharmaceutical Wholesale Business - The pharmaceutical wholesale segment generated revenue of 39.052 billion yuan, accounting for over 95% of total revenue, serving more than 8,000 medical institutions [2] - The company is enhancing its "pharmaceutical + internet" strategy, with the online platform "Zhongyao Cloud Business" achieving a transaction volume of approximately 1 billion yuan, a year-on-year increase of 72% [2] Retail Business - The retail segment achieved revenue of 1.947 billion yuan, with brands like "Heping Pharmacy" covering over 850 stores across 22 provinces [2] - The company has opened 616 stores offering outpatient coordination services, improving patient access to medication and health management [2] Product and Service Diversification - The company operates over 280,000 product specifications, with pharmaceutical revenue reaching 33.668 billion yuan and traditional Chinese medicine revenue at 7.210 billion yuan [2] - The company has established standardized planting bases for traditional Chinese medicine and enhanced production capabilities through modern workshops and AI technology [2] Medical Device and Specialty Drugs - The medical device segment generated revenue of 6.884 billion yuan, with 41 SPD projects implemented to improve hospital supply chain management [3] - Revenue from narcotic drugs and Class I psychotropic drugs was 1.736 billion yuan, ensuring stable supply and efficient distribution [3] Innovation and Development - The company is focusing on high-end generic drugs, specialty traditional Chinese medicine, and innovative drug development [3] - Four products, including Mirabegron sustained-release tablets, were approved during the reporting period, with three already in commercial production [3]